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Hemophilia A (HA) is a bleeding disorder caused by factor VIII (FVIII)
deficiency. FVIII replacement therapy can reduce bleeding but is
expensive, inconvenient, and complicated by development of an-
tibodies that inhibit FVIII activity in 30% of patients. Neonatal
hepatic gene therapy could result in continuous secretion of FVIII
into blood and might reduce immunological responses. Newborn
HA mice and dogs that were injected i.v. with a retroviral vector
(RV) expressing canine B domain-deleted FVIII (cFVIII) achieved
plasma cFVIII activity that was 139  22% and 116  5% of values
found in normal dogs, respectively, which was stable for 1.5 yr.
Coagulation tests were normalized, no bleeding had occurred, and
no inhibitors were detected. This is a demonstration of long-term
fully therapeutic gene therapy for HA in a large animal model.
Desmopressin (DDAVP; 1-deamino-[D-Arg8]vasopressin) is a drug
that increases FVIII activity by inducing release of FVIII complexed
with von Willebrand factor from endothelial cells. It has been
unclear, however, if the FVIII is synthesized by endothelial cells or
is taken up from blood. Because the plasma cFVIII in these RV-
treated dogs derives primarily from transduced hepatocytes, they
provided a unique opportunity to study the biology of the DDAVP
response. Here we show that DDAVP did not increase plasma cFVIII
levels in the RV-treated dogs, although von Willebrand factor was
increased appropriately. This result suggests that the increase in
FVIII in normal dogs after DDAVP is due to release of FVIII synthe-
sized by endothelial cells.
retroviral vector  inhibitor  B domain-deleted
Hemophilia A (HA) is an X-linked bleeding disorder with anincidence of 1 in 5,000 males (1). Severe HA patients have
1% of normal factor VIII (FVIII) activity (normal levels are
200 ngml) and frequently bleed spontaneously. Patients with
1–5% of normal activity have moderately severe bleeding, and
patients with 5–25% of normal activity usually bleed only with
surgery or trauma. HA is generally treated with FVIII protein
injections, which are expensive and inconvenient. An alternative
treatment for mild HA is desmopressin (DDAVP; 1-deamino-
[D-Arg8]vasopressin), which releases FVIII complexed with von
Willebrand factor (VWF) from endothelial cells (2). It has been
unclear, however, as to whether this stored FVIII is synthesized
de novo in endothelial cells or taken up from blood, because both
endothelial cells and hepatocytes express FVIII mRNA (3).
HA is a candidate for gene therapy, which involves transfer of
a FVIII gene into cells that secrete functional protein into blood.
The 7-kb FVIII cDNA encodes a 2,332-aa protein that is cleaved
intracellularly to an N-terminal heavy chain (A1, A2, and B
domains) and a C-terminal light chain (A3, C1, and C2 domains)
(4). Because the B domain released after FVIII activation is not
necessary for function, B domain-deleted (BDD) constructs of
only 4.5 kb have been used in most gene therapy approaches.
Stable and therapeutic levels of FVIII have been achieved in HA
mice (reviewed in refs. 5–9) by transduction of liver with gamma
retroviral vectors (RVs) [20% of normal FVIII (10)], adeno-
viral vectors [50% of normal (11–15)], lentiviral vectors [5%
of normal (16, 17)], hydrodynamic injection of plasmid DNA
[300% of normal (18)], and adeno-associated virus vectors
[2–100% of normal (19–23)]. Ex vivo gene therapy of endothelial
cells (24) or hematopoietic stem cells (25) has also resulted in
50% of normal FVIII activity.
Gene therapy for HA has been less effective in large animals
and humans than in mice. An adeno-associated virus vector
resulted in 3% of normal FVIII activity in HA dogs (26).
Adenoviral vectors resulted in high initial expression (25% of
normal) in HA dogs (11, 27, 28) and normal primates (29), but
expression fell over time. A helper-dependent adenoviral vector
had low expression in one patient and the trial was discontinued
because of inflammatory responses (9). Injection of a gamma
RV (30) or implantation of ex vivo-transduced autologous
fibroblasts (31) resulted in undetectable or low (5% of normal)
levels of FVIII that fell over time.
A major problem with protein or gene therapy for HA is the
development of inhibitors, which are antibodies that inhibit the
coagulation function of FVIII. Up to 30% of HA patients
develop inhibitors; development of inhibitors usually occurs in
patients with inversions, large deletions, or nonsense mutations
(32). Inhibitors have also developed in mice, dogs, and primates
that received gene therapy, and these inhibitors have varied
according to the species and strain, the dose and method of
delivery, the age at the time of transfer, and the underlying
mutation in the recipient.
We previously demonstrated that neonatal i.v. injection of a
gamma RV resulted in transduction of hepatocytes, which
secreted factor IX in hemophilia B mice and dogs without
inhibitor development (33, 34). We therefore tested whether this
large-capacity vector might allow fully therapeutic expression of
FVIII to be achieved without inhibitor development after neo-
natal transfer in mice and dogs with HA. In addition, the
hepatocyte-restricted expression achieved with this gene transfer
approach provided a unique situation in which to further inves-
tigate the biology of the DDAVP response in dogs.
Methods
Reagents. Reagents were obtained from Sigma-Aldrich unless
otherwise stated.
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RV. The plasmid pBS KS()-canine SQN FVIII contains a 4.5-kb
canine BDD-FVIII (cFVIII) cDNA with 6 nt of 5 and no 3
untranslated sequence (19). The cFVIII cDNA was ligated into the
NotI site of hAAT-WPRE-767 (35) to generate hAAT-cFVIII-
WPRE-775. An amphotropic RV-packaging cell line was prepared
as described (35). High-titer clones were identified by using con-
ditioned media to infect NIH 3T3 cells and determination of cFVIII
activity from infected cells by COATEST FVIII assay as described
below. Large-scale preparation of RV and the assay for replication-
competent retrovirus were performed as described (35). RV titer
was determined after freezethaw once by transducing NIH 3T3
cells and determination of the RV DNA copy number in these cells
1 wk later by real-time PCR as detailed below. The RV injectate
contained 0.1 unitml cFVIII protein.
Animal Procedures. National Institutes of Health and Department of
Agriculture guidelines for the care and use of animals in research
were followed. HA mice (129  C57BL6) (36) were injected with
RV as neonates at 2–3 d after birth via the temporal vein or as adults
at 6 wk via the tail vein. Blood obtained from the retroorbital plexus
with a plain capillary tube was mixed with a 110 volume of 3.2%
sodium citrate.
Two dogs from the Chapel Hill HA colony (37) were injected i.v.
with two doses of RV at 3 d after birth. H18 was male, weighed
379 g, and received two doses of RV separated by 7 h. H22 was
female, weighed 409 g, and received two doses separated by 24 h.
DDAVP (GensiaCicor Pharmaceuticals, Irvine, CA) was injected
i.v. at 5 gkg into normal and RV-treated HA dogs at 3.5 yr and
8 mo of age, respectively. Plasma was tested for VWF antigen by
ELISA and cFVIII activity by COATEST assay as detailed below.
COATEST FVIII Assay. Plasma FVIII activity was measured by a
COATEST FVIII kit (DiaPharma, West Chester, OH) with bovine
reagents. Samples were tested after freezethaw once. The assay
included four steps. First, 10 l of sample was incubated with 20 l
of a mixture of phospholipid, factor IXa, and factor X for 5 min at
37°C. Second, 10 l of 25 mM CaCl2 was added and the mixture was
incubated for 5 min at 37°C. Third, 20 l of chromogenic substrate
(S-2222) and thrombin inhibitor (I-2581) were added and the
mixture was incubated for 5 min at 37°C. Finally, 10 l of 20% acetic
acid was added, and the absorbance at 405 and 490 nm was
measured. The dog plasma in the standards had various ratios of
normal to HA plasma. Because varying the amount of plasma from
different species might affect coagulation times, the samples and
standards contained 0.1 l of total mouse plasma and 0.5 l of total
dog plasma in PBS for the mouse study, or 1 l of total dog plasma
in PBS for the dog study. Samples from RV-treated animals were
diluted in homologous FVIII-deficient plasma if necessary.
Coagulation Assays. The quantitative activated partial thromboplas-
tin time (Q-aPTT) assay described in ref. 33 was performed for the
mice with 10 l of mouse plasma, 10 l of cFVIII-deficient dog
plasma, and 80 l of hFVIII-deficient human plasma. Standards
used 10 l of HA mouse plasma, 10–0 l of normal dog plasma,
0–10 l of cFVIII-deficient dog plasma, and 80 l of hFVIII-
deficient human plasma. Samples from RV-treated mice were
diluted with HA mouse plasma if necessary. The tail-clip bleeding
assay was performed on 4-mo-old mice as described (33), except the
endpoint was 6 h, and bleeding was determined by visual inspection
after blotting the tail on filter paper.
Both straight aPTT and Q-aPTT assays were performed for
dog samples. In the straight aPTT assay, 100 l of plasma from
normal, HA, or RV-treated dogs was used. In the Q-aPTT assay,
40 l of RV-treated dog plasma (diluted in cFVIII-deficient
plasma if necessary) was mixed with 60 l of PBS. Standards
used 0–40 l of normal dog plasma, 40–0 l of cFVIII-deficient
dog plasma, and 60 l of PBS.
Bethesda Assay. Samples for inhibitor assays were heat-inactivated
at 56°C for 1 h. For mice, 5 l of mouse plasma, 5 l of normal dog
plasma, and 40 l of PBS were incubated at 37°C for 2 h, and then
50 l of hFVIII-deficient human plasma was added for the aPTT
assay. Standards used 0–5 l of normal dog plasma and 5–0 l of
cFVIII-deficient dog plasma incubated with 5 l of heat-inactivated
HA mouse plasma and 40 l of PBS at 37°C for 2 h, and then 50
l of hFVIII-deficient human plasma was added, and aPTT was
performed. The dilution factor was 1 if 5 l of undiluted mouse
plasma was used. If necessary, samples were diluted in heat-
inactivated HA mouse plasma. Samples from dogs were assayed in
a similar fashion, except 5 l of heat-inactivated RV-treated dog
plasma was used. One Bethesda unit per milliliter inhibits 50% of
the coagulation activity, and the limit of sensitivity was 1 Bethesda
unitml.
Immunoassay for VWF. Plasma VWF antigen levels were deter-
mined by ELISA (38) using anti-human VWF antibodies
(DAKO) and diluted normal dog plasma for the standards.
Analysis of RV DNA and RNA. The RV DNA and RNA distribution
was determined as described (39). Briefly, RNA or DNA was
isolated from organs, and cDNA reverse-transcribed from 0.1 g of
RNA or 100 ng of genomic DNA was analyzed by real-time PCR
for the woodchuck hepatitis virus posttranscriptional regulatory
element (WPRE) sequence, with normalization to the -actin
sequence. RNA and DNA from nontransduced mouse or dog liver
and RNA from transduced mice that did not receive reverse
transcriptase were used as controls to demonstrate a lack of
contamination.
Results
RV Expressing cFVIII. The BDD-cFVIII cDNA (Fig. 1A) was cloned
into an RV downstream of the liver-specific human 1-antitrypsin
(hAAT) promoter (Fig. 1B) and used to generate an amphotropic
RV. After large-scale preparation, the titer of concentrated RV was
1–3  108 transducing units (TU)ml, and there were 10 copies
of replication-competent retrovirus per milliliter. NIH 3T3 cells
infected with this RV at a multiplicity of infection of 1 produced
0.3  0.002 unit of cFVIII per 24 h per 106 cells as determined by
COATEST FVIII assay.
cFVIII Expression and Inhibitor Levels in Mice. HA mice (129 
C57BL6) have a disruption in exon 16 within the A3 domain of the
FVIII gene and produce heavy but not light chains (40, 41). They
frequently produce inhibitors after therapy with FVIII proteins or
genes from mouse, dog, or human. Neonatal mice were injected i.v.
with 1  1010 TUkg RV to evaluate the effect of neonatal gene
Fig. 1. RV vector. (A) BDD cFVIII cDNA. cFVIII cDNA lacks all but 22 aa of the
908-aa B domain and has a covalent linkage between S743 and Q1630. The
intracellular cleavage site at R1648 and the thrombin cleavage sites at R740
and R1689 are retained. (B) hAAT-cFVIII-WPRE. This amphotropic gamma RV
contains intact LTRs, an extended packaging signal (), the liver-specific
hAAT promoter, the BDD cFVIII cDNA, and the WPRE. Arrows indicate that an
RNA can initiate from the LTR or the hAAT promoter.











therapy. They achieved 139  22% of normal cFVIII activity in
plasma by COATEST assay (Fig. 2A). The expression of cFVIII was
stable for 1.5 yr, and none of 11 mice developed anti-cFVIII
inhibitory antibodies (Fig. 2C). To test the ability of HA mice to
develop inhibitors to cFVIII, RV was injected i.v. into 6-wk-old
adult mice. cFVIII expression in these mice was low and transient
(Fig. 2B) because of low levels of replicating hepatocytes in adult
mice. All nine mice developed high titers of cFVIII inhibitors (Fig.
2D). The frequency of inhibitor formation in HA mice after
neonatal gene therapy was significantly lower than after adult gene
therapy (P  0.001, Fisher exact test). cFVIII activity determined
by Q-aPTT assay showed that RV-treated mice had 26  6% of
normal activity, which was only 26  3% of that determined by
COATEST assay (103% of normal) for the same samples (Fig. 2E).
All HA mice that were treated with RV as newborns achieved
hemostasis at 6 h after tail-clip, although untreated HA mice did
not (P  0.001, Fisher exact test) (Fig. 2F). We conclude that the
cFVIII produced after neonatal gene therapy was functional in vitro
and in vivo.
RV DNA and RNA Distribution in Neonatal Mice. The lack of antibodies
in mice after neonatal delivery could be due to liver-restricted
expression, because RV RNA levels in nonhepatic organs were
0.3% or less of that in liver at 6 mo after neonatal gene therapy in
a previous study (39). However, because DNA transfer to nonhe-
patic organs was up to 10% of that in liver, and the LTR promoter
can shut off over time in mice, higher expression might occur in
nonhepatic cells shortly after gene transfer. Indeed, Fig. 3 shows
that spleen had 66  26% and 31  12% as much DNA and RNA,
respectively, as liver at 1 wk after neonatal gene transfer to
C57BL6 mice. This finding makes it unlikely that liver-restricted
expression accounts for the lack of an antibody response.
Neonatal Gene Therapy in HA Dogs. RV transduction was performed
on neonatal HA dogs from the Chapel Hill colony, which have an
inversion between intron 22 and a sequence upstream of the
promoter (37). These dogs express an RNA that is truncated within
the C1 domain and do not usually develop inhibitory antibodies to
cFVIII protein (T.C.N., unpublished data). H18 and H22 received
0.8  1010 TUkg RV at 3 d after birth. The platelet count fell
to below normal at 78,000  12,000 at 24 h (P 	 0.03 for 24 h vs.
pre-gene-transfer values) and 102,000  22,100 at 48 h (P 	 0.05
for 48 h vs. pre-gene-transfer values), but returned to normal by day
4 (Fig. 4A). This fall in platelets was similar to that observed
previously with a similar dose of RV (33) but did not occur when
the dose was reduced to 3  109 TUkg or less (34). Liver function
tests and other blood counts were not affected by the gene therapy
and were similar to values reported previously.
The whole-blood clotting time (WBCT) was corrected at the first
time of analysis after gene transfer and has remained normal for 1.5
yr thus far (Fig. 4B). The straight aPTT fell progressively during the
first 3 mo, and thereafter was usually normal for H18 and near-
normal for H22 (Fig. 4C). The average COATEST cFVIII activities
in plasma collected from 3 to 17 mo after gene therapy were 129 
7% and 101  4% of normal for H18 and H22, respectively (Fig.
4D). The functional cFVIII activity in the Q-aPTT assay was 61 
5% and 35  5% of normal for H18 and H22, respectively (Fig. 4E).
Thus, the cFVIII activity by COATEST assay was 2.5-fold that
observed by Q-aPTT assay for the RV-treated dogs. No bleeding
episodes have occurred, and no cFVIII inhibitors were detected by
the Bethesda assay (Fig. 4F).
Liver Vector DNA After Neonatal Gene Therapy in Mice and Dogs.
Livers were obtained from three RV-treated HA mice at 12 mo
after neonatal transfer. Real-time PCR demonstrated that
there were 1.9  0.5 RV DNA copies per cell in the liver for
mice whose average cFVIII levels by COATEST assay were
106  2% of normal (Fig. 5). The lower copy number in the
liver observed at 1 wk after transduction in mice (Fig. 3) may
be due to substantial contamination with hematopoietic cells
in the liver at the early time. DNA from livers obtained at 14
mo after neonatal gene therapy contained 0.16 and 0.10 copies
of RV DNA per cell in the dogs with 129% and 101% of normal
cFVIII activity, respectively (Fig. 5). Thus, although mice and
dogs had similar FVIII COATEST activity in plasma, mice had
14-fold more copies of RV DNA than did dogs.
Fig. 2. Gene therapy with hAAT-cFVIII-WPRE in HA mice. (A) cFVIII activity
after neonatal transduction. Neonatal HA mice were injected i.v. with 1  1010
TUkg hAAT-cFVIII-WPRE at 2 or 3 d after birth [neonatal gene therapy (GT)],
and the plasma cFVIII activity was measured by COATEST assay. Normal mice
have 60–160% of normal cFVIII activity (gray shading), and HA mice have 1%
of normal activity (cross-hatching). (B) cFVIII activity after adult transduction.
HA mice (6-wk-old) were injected i.v. with 1  1010 TUkg (n 	 3; F) or 3  109
TUkg (n 	 6; E) of hAAT-cFVIII-WPRE (adult GT). Plasma cFVIII levels were
measured by COATEST FVIII assay. (C) cFVIII inhibitors after neonatal trans-
duction. Plasma from the mice described in A were tested for anti-cFVIII
inhibitory antibodies by Bethesda assay. (D) cFVIII inhibitors after adult trans-
duction. Plasma from the mice described in B was tested for cFVIII inhibitors by
the Bethesda assay. (E) Coagulation activity in vitro. The samples from the mice
described for A were tested at 4 and 15 mo to ensure reproducibility. The
average cFVIII activities from the COATEST assay are plotted vs. the average
activities from the Q-aPTT assay for the same samples for individual mice. The
line represents values where the percentage functional activities from each
assay are the same. (F) Hemostasis assay in vivo. Tail-clip was performed at 4
mo after transduction in the neonatal RV-treated mice (HA  RV) described for
A, and the percentage of animals that achieved hemostasis within 6 h was
determined. Tail-clip was also performed on age-matched untreated HA mice
and C57BL6 normal mice.
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The Effect of DDAVP on Dogs. Administration of DDAVP to humans
(42) or dogs (38) increases both VWF and FVIII within 30–60 min.
In this study, DDAVP was injected i.v. at 5 gkg into normal dogs
(n 	 4) or RV-treated HA dogs (H18 and H22). In normal dogs,
both FVIII and VWF levels increased to 1.5-fold normal between
0.25 and 1 h after DDAVP (Fig. 6A). In contrast, FVIII levels in
H18 did not increase after DDAVP, although VWF levels increased
to 2.5-fold normal (P  0.005 for comparison of relative cFVIII to
relative VWF levels at each time between 0.25 and 1 h after
DDAVP, Student’s t test) (Fig. 6B). Similarly, DDAVP had no
effect on FVIII activity in H22, although VWF levels increased to
1.6-fold normal (P  0.05, Student’s t test) (Fig. 6C). Because
plasma cFVIII in RV-treated dogs probably primarily derives from
transduced hepatocytes that secrete cFVIII into blood, the increase
of FVIII in normal animals is likely due to release of FVIII that is
synthesized in endothelial cells, rather than taken up from the
blood.
Discussion
Neonatal Gene Therapy Corrects HA in Mice and Dogs. Neonatal
transduction of a gamma RV resulted in stable expression of cFVIII
in HA models. The plasma cFVIII activity by COATEST assay was
139  22% and 116  5% of normal in RV-treated HA mice and
dogs, respectively. The COATEST cFVIII activity was 4-fold and
2.5-fold the activity determined by Q-aPTT assay in RV-treated
HA mice and dogs, respectively. This discrepancy may be caused by
the BDD construct, as recombinant human BDD-FVIII has 2-
fold more activity by COATEST assay than by aPTT assay (43). All
RV-treated HA mice achieved hemostasis after bleeding challenge.
Both WBCT and aPTT were normalized in the RV-treated HA
dogs, and no bleeding episodes have occurred. The FVIII levels
achieved in this study are 20-fold higher than the long-term
expression with other vectors for HA in dogs (11, 26–29).
The fact that cFVIII plasma levels in dogs were almost as high
as in mice was surprising because expression in C57BL6 mice
was 10-fold higher than in dogs when a similar dose of RV per
kg was given in our previous studies (33, 35, 39). Furthermore,
in this study, mice had 14-fold more RV copies per cell in liver
than did dogs. Canine FVIII may not interact well with murine
VWF, or may be poorly secreted in mice. It is unclear why
transduction was more efficient in C57BL6 mice than in dogs.
Attempts to quantify the percentage of replicating hepatocytes
in mice were not successful because of the large numbers of
hematopoietic cells in livers of newborns.
Neonatal Gene Therapy Did Not Induce Inhibitors in HA Mice or Dogs.
Inhibitor formation is a major complication in the treatment of HA
patients with FVIII protein and is a critical challenge for gene
therapy. Inhibitors have generally developed after gene therapy to
adult immunocompetent HA mice. However, in this study, none of
11 HA mice developed FVIII inhibitors after neonatal gene therapy
with RV, whereas all mice developed FVIII inhibitors after adult
transduction. Our results in mice with cFVIII differ from a previous
study that showed that 50% of HA mice produced inhibitors after
neonatal transduction of a vesicular stomatitis virus G glycoprotein
pseudotyped RV expressing human BDD-FVIII (10). Because the
human FVIII (hFVIII) levels were low at the first time of evaluation
in animals with inhibitors, inhibitor formation may have been
induced by low levels of hFVIII, as low expression of human factor
IX is more likely to induce antibodies than high expression in adult
mice (44). Other possible reasons for this discrepancy are that: (i)
the human BDD-FVIII may be more immunogenic than canine
BDD-FVIII in mice; (ii) the vesicular stomatitis virus G glycopro-
tein envelope may induce more inflammatory responses than the
amphotropic envelope; or (iii) the genetic background of the mice
may be different. Further experiments are needed to evaluate this
discrepancy. Liver-specific promoters may prevent an antibody
response by avoiding expression in antigen-presenting cells. How-
ever, liver-restricted expression is not the mechanism of tolerance
Fig. 3. RV DNA and RNA distribution in neonatal mice. Normal C57BL6 mice
were injected i.v. with 1  1010 TUkg hAAT-cFVIII-WPRE at 2–3 d after birth
(n 	 5) and killed 1 wk later. Real-time PCR on genomic DNA and real-time
RT-PCR on RNA was performed to detect RV DNA and RNA, respectively. The
amounts of RV DNA and RNA are plotted as the average relative to that in the
liver  SEM. The average RV DNA in the liver was 0.3  0.03 copy per cell.
Fig. 4. Neonatal gene therapy with hAAT-cFVIII-WPRE in HA dogs. Two HA
dogs (H18 and H22) were injected i.v. at 3 d after birth with 0.9  1010 and 0.7 
1010 TUkg hAAT-cFVIII-WPRE, respectively, as detailed in Methods. The
ranges of values in normal and HA dogs for each assay are indicated as gray
and cross-hatched regions, respectively. (A) Platelets were evaluated at the
indicated times after the first dose of RV. (B) The WBCT is 8–13 min for normal
dogs and 60 min for HA dogs. (C) aPTT. (D) Plasma cFVIII activity. Plasma cFVIII
activity was determined by COATEST assay. The normal range of cFVIII is
60–160%, and HA dogs have 1% of normal cFVIII activity. (E) Comparison of
COATEST and Q-aPTT cFVIII activities in dogs. cFVIII functional activity in
plasma obtained from dogs at 9–11 mo after transduction was analyzed by
COATEST and Q-aPTT assays. (F) cFVIII inhibitors were tested by Bethesda
assay.











here because RNA levels in spleen were 31% of the level in liver in
mice at 1 wk after gene transfer, which is likely due to transcription
from the LTR. The low expression reported previously in spleen at
6 mo (0.3% of that in liver) after a similar gene transfer procedure
(39) likely reflects shut-down of the LTR.
There was also no inhibitor formation in the RV-treated dogs
in this study. This result is consistent with the hypothesis that
neonatal gene therapy results in tolerance to cFVIII in HA dogs;
although the small number of animals analyzed (n 	 2) and the
relatively low incidence of inhibitor formation (0–50%) in dogs
with a similar mutation after cFVIII protein (45) or gene (11,
26–28) therapy to adults make it impossible to be certain that this
will be consistently effective. Studies using the vector expressing
cFVIII and HA dogs from an inhibitor-prone lineage, or a vector
expressing hFVIII in mice and dogs, followed by challenge with
hFVIII protein, are needed to demonstrate true tolerance.
DDAVP Did Not Increase FVIII Activity in RV-Treated Dogs. FVIII is
stabilized by VWF in the circulation. VWF is produced by endo-
thelial cells and megakaryocytes and is stored in Weibel–Palade
bodies in endothelial cells and -granules in platelets (4). DDAVP
causes VWF and FVIII to be released from endothelial cells, and
this release increases the plasma levels of both VWF and FVIII (2).
However, the source of the released FVIII after DDAVP stimu-
lation has not been determined (3). Liver is a major site of FVIII
production because liver transplantation completely corrects HA
(46), and hepatocytes express FVIII mRNA (47). However, end-
stage liver disease does not cause a decrease in FVIII, FVIII mRNA
is found in other organs, and spleen and lung transplantation can
ameliorate HA (3). Expression of FVIII in other organs may be due
to endothelial cells because endothelial cells express FVIII mRNA
and protein in vitro (47) and store FVIII with VWF in Weibel–
Palade bodies (48). Thus, there are two possible sources of stored
FVIII in endothelial cells: uptake from blood or de novo synthesis
by endothelial cells.
In this study, the effect of DDAVP on HA dogs after neonatal
hepatic gene therapy with an RV expressing cFVIII was tested. This
gene transfer approach resulted in high expression in hepatocytes
without detectable expression in endothelial cells, as assessed by
histochemical staining at 1 wk after gene transfer in dogs (ref. 35
and L.X. and K.P.P., unpublished data). We hypothesized that if
DDAVP increases FVIII levels in this dog model, it would indicate
that the FVIII increase is due to release of FVIII that is taken up
from blood by endothelial cells. Alternatively, if no increase in
FVIII occurs after DDAVP stimulation, it would suggest that the
FVIII increase in normal dogs is due to release of protein that is
synthesized by endothelial cells. DDAVP increased both FVIII and
VWF levels in normal dogs to 1.5-fold normal at 15–60 min after
stimulation, which was consistent with a previous study (38).
However, in RV-treated HA dogs, FVIII levels did not change,
although VWF levels increased to 2.5- or 1.6-fold normal. This
result suggests that the FVIII increase in normal dogs after
DDAVP administration is probably due to release of FVIII that is
synthesized by endothelial cells, although it is possible that our
result is affected by the use of a BDD construct. Our data
demonstrate that DDAVP will not be effective at increasing FVIII
activity in patients that receive liver-directed gene therapy with
BDD-hFVIII and only achieve partial correction. Such patients
would need to be treated with factor replacement if bleeding
episodes occur.
Implications for Gene Therapy. This study demonstrated that
neonatal gene therapy with a gamma RV resulted in fully
therapeutic levels of cFVIII in HA mice and dogs without
inhibitor formation. This approach may ultimately be used to
reduce the bleeding manifestations in humans with HA.
However, it will be necessary to demonstrate that neonatal
RV-mediated gene therapy has a very low risk of insertional
mutagenesis or germ-line transmission in large animals before
using this approach in humans, and addition of suicide or
insulator elements may be necessary. In addition, it will be
important to determine whether neonatal tolerance is effective
at preventing antibody formation in primates before using
this approach in humans that are at high risk of inhibitor
formation.
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